The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Advances in the Treatment of Prolactinomas
Abstract
Prolactinomas account for approximately 40% of all pituitary adenomas and are an important cause of hypogonadism and infertility. The ultimate goal of therapy for prolactinomas is restoration or achievement of eugonadism through the normalization of hyperprolactinemia and control of tumor mass. Medical therapy with dopamine agonists is highly effective in the majority of cases and represents the mainstay of therapy. Recent data indicating successful withdrawal of these agents in a subset of patients challenge the previously held concept that medical therapy is a lifelong requirement. Complicated situations, such as those encountered in resistance to dopamine agonists, pregnancy, and giant or malignant prolactinomas, may require multimodal therapy involving surgery, radiotherapy, or both. Progress in elucidating the mechanisms underlying the pathogenesis of prolactinomas may enable future development of novel molecular therapies for treatment-resistant cases. This review provides a critical analysis of the efficacy and safety of the various modes of therapy available for the treatment of patients with prolactinomas with an emphasis on challenging situations, a discussion of the data regarding withdrawal of medical therapy, and a foreshadowing of novel approaches to therapy that may become available in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Dopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752
Hypopituitarism Following External Radiotherapy for Pituitary Tumours in Adults
LITTLEY, M. D., SHALET, S. M., BEARDWELL, C. G., AHMED, S. R., APPLEGATE, G., & SUTTON, M. L. (1989) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068308 · Cited by 444
Giant prolactinomas in men: efficacy of cabergoline treatment
Corsello, S. M., Ubertini, G., Altomare, M., Lovicu, R. M., Migneco, M. G., Rota, C. A., & Colosimo, C. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01770.x · Cited by 148
Cited by
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844
Diagnosis and Treatment of Pituitary Adenomas: A Review
Molitch, M. E. (2017) · JAMA · doi:10.1001/jama.2016.19699 · Cited by 933
Self-citationBriet, C., Salenave, S., Bonneville, J.-F., Laws, E. R., & Chanson, P. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1042 · Cited by 409
Petersenn, S., Fleseriu, M., Casanueva, F. F., Giustina, A., Biermasz, N., Biller, B. M. K., Bronstein, M., Chanson, P., Fukuoka, H., Gadelha, M., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00886-5 · Cited by 411
Self-citationPlace of Cabergoline in Acromegaly: A Meta-Analysis
Sandret, L., Maison, P., & Chanson, P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2443 · Cited by 314
Metadata
- Authors
- Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2006-05-26
- Volume
- 27
- Issue
- 5
- Pages
- 485-534
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2017283375
- Cited by
- 824
- References
- 7
- FWCI
- 24.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in the Treatment of Prolactinomas. https://app.cochat.ai/papers/10.1210/er.2005-9998
- The paper
- Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006). Advances in the Treatment of Prolactinomas. Endocrine Reviews. https://doi.org/10.1210/er.2005-9998
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
